NASDAQ:NVNO enVVeno Medical (NVNO) Stock Price, News & Analysis → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free NVNO Stock Alerts $5.06 -0.03 (-0.59%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$5.05▼$5.3050-Day Range$4.62▼$6.6552-Week Range$2.51▼$6.97Volume51,565 shsAverage Volume109,809 shsMarket Capitalization$67.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get enVVeno Medical alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About enVVeno Medical Stock (NASDAQ:NVNO)enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Read More NVNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVNO Stock News HeadlinesApril 30, 2024 | americanbankingnews.comenVVeno Medical (NASDAQ:NVNO) Trading 0.8% Higher April 24, 2024 | finance.yahoo.comenVVeno Medical Corporation (NVNO)May 7, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 24, 2024 | finance.yahoo.comPositive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross SymposiumApril 16, 2024 | finance.yahoo.comNew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024April 11, 2024 | uk.investing.comenVVeno Medical hires new CCO to guide transitionApril 10, 2024 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial OfficerApril 9, 2024 | finance.yahoo.comenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial OfficerMay 7, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 16, 2024 | finance.yahoo.comNVNO Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comenVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno OpportunityMarch 6, 2024 | finance.yahoo.comPositive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual MeetingMarch 3, 2024 | finance.yahoo.comCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In GrowthFebruary 29, 2024 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateFebruary 29, 2024 | benzinga.comRecap: enVVeno Medical Q4 EarningsFebruary 29, 2024 | finance.yahoo.comenVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateFebruary 20, 2024 | finance.yahoo.comTopline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024January 6, 2024 | finance.yahoo.comenVVeno Medical Corporation's (NASDAQ:NVNO) Path To ProfitabilityDecember 29, 2023 | ca.finance.yahoo.comNVNO Jan 2024 5.000 callDecember 14, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH SymposiumDecember 14, 2023 | finance.yahoo.comenVVeno Medical Posts Company Highlights and Materials from 2023 VEITH SymposiumNovember 16, 2023 | finance.yahoo.comenVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH SymposiumOctober 26, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 26, 2023 | msn.comenVVeno Medical files to sell 14.71M shares for holdersOctober 26, 2023 | msn.comenVVeno Medical reports Q3 resultsOctober 26, 2023 | finance.yahoo.comenVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 12, 2023 | finance.yahoo.comenVVeno Medical to Participate at the Virtual Investor Ask the CEO ConferenceSee More Headlines Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVNO CUSIPN/A CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.17% Return on Assets-64.68% Debt Debt-to-Equity RatioN/A Current Ratio34.22 Quick Ratio34.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book1.46Miscellaneous Outstanding Shares13,320,000Free Float11,053,000Market Cap$67.40 million OptionableOptionable Beta1.10 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesRobert Andrew BermanChief Executive Officer & DirectorCraig T. GlynnChief Financial Officer & TreasurerMarc H. GlickmanChief Medical Officer & Senior Vice PresidentHamed AlaviVice President-Research, Development & QualityKey CompetitorsMonogram OrthopaedicsNASDAQ:MGRMPro-DexNASDAQ:PDEXSensus HealthcareNASDAQ:SRTSSEP AcquisitionNASDAQ:SEPAAutonomix MedicalNASDAQ:AMIXView All CompetitorsInsiders & InstitutionsRIA Advisory Group LLCBought 43,666 shares on 5/3/2024Ownership: 0.328%Janney Montgomery Scott LLCBought 34,140 shares on 5/1/2024Ownership: 0.256%Fermata Advisors LLCBought 6,873 shares on 4/12/2024Ownership: 0.174%Kingdon Capital Management L.L.C.Bought 400,000 shares on 3/18/2024Ownership: 4.648%Hamed AlaviSold 8,334 sharesTotal: $51,837.48 ($6.22/share)View All Insider TransactionsView All Institutional Transactions NVNO Stock Analysis - Frequently Asked Questions How have NVNO shares performed in 2024? enVVeno Medical's stock was trading at $5.14 on January 1st, 2024. Since then, NVNO stock has decreased by 1.6% and is now trading at $5.06. View the best growth stocks for 2024 here. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.32) earnings per share (EPS) for the quarter. Who are enVVeno Medical's major shareholders? enVVeno Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include RIA Advisory Group LLC (0.33%), Janney Montgomery Scott LLC (0.26%) and Fermata Advisors LLC (0.17%). Insiders that own company stock include Francis Duhay, Gmt Capital Corp, Hamed Alavi, Marc H Glickman, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava. View institutional ownership trends. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVNO) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & CompanyThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.